DHR · News · 20261104N

Regulatory Approval Milestones

DANAHER CORP /DE/ · 2026-11-04 · Importance null · Surprise null

The U.S. FDA cleared Cepheid’s Xpert Hemorrhagic Fever Panel multiplex PCR test, which detects Ebola, Marburg, Lassa, and Crimean Congo hemorrhagic fever viruses from one patient sample. The panel runs on Danaher’s GeneXpert system and expands its use in high-consequence infectious disease and outbreak-preparedness settings. The clearance was reported on November 4, 2026; the coverage did not quantify its financial impact.